Trials / Active Not Recruiting
Active Not RecruitingNCT04159987
Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Spinraza intrathecal injection | The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen). |
Timeline
- Start date
- 2020-02-25
- Primary completion
- 2024-07-19
- Completion
- 2025-12-31
- First posted
- 2019-11-12
- Last updated
- 2025-12-03
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04159987. Inclusion in this directory is not an endorsement.